Praxbind earns new UK status as antidote to Pradaxa
Privately-owned German pharma Boehringer Ingelheim’s Praxbind (idarucizumab) has been added to the UK’s national antidote list.
Praxbind is the only agent to be licensed in the UK to reverse the anticoagulant effect of a non-vitamin K antagonist oral anticoagulant (NOAC), and it has now been included in the latest Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments.
This drug was launched in the UK in December 2015 and is licensed for use in adults treated with Boehringer’s Pradaxa (dabigatran etexilate), when rapid reversal of its anticoagulant effects is required for emergency surgery or urgent procedures, or in life-threatening or uncontrolled bleeding.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze